---
title: "The Huaxia Science and Technology Innovation Medical ETF (588130) turned red during trading, with turnover exceeding 50 million yuan."
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43449126.md"
description: "On August 18, major A-share indices adjusted collectively. Amid market volatility, the biopharma sector demonstrated resilience. As of 10:20, the Huaxia Sci-Tech Medical ETF (588130) rose 0.37%, with its holdings including Oulin Bio (+4.30%), Yifang Bio-U (+2.58%), Wanhua Biotechnology (+2.51%), and BeiGene (+2.47%). In terms of liquidity, intraday turnover exceeded RMB 50 million with a turnover rate over 10%. Despite short-term market fluctuations, capital flows are showing a positive attitude toward the hard-tech medical track. Latest data shows..."
datetime: "2026-08-18T04:34:21.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43449126.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43449126.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43449126.md)
author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)"
---

# The Huaxia Science and Technology Innovation Medical ETF (588130) turned red during trading, with turnover exceeding 50 million yuan.

On August 18, major A-share indices adjusted collectively. Amid market volatility, the biopharma sector demonstrated resilience. By 10:20, the Huaxia Science and Technology Innovation Board Biopharmaceutical ETF (588130) rose 0.37%, with its holdings including Oulin Bio (+4.30%), Yifang Bio-U (+2.58%), Wanhua Biological (+2.51%), and BeiGene (+2.47%). In terms of liquidity, intraday turnover exceeded RMB 50 million, with a turnover rate surpassing 10%.

Despite short-term market fluctuations, capital flows are signaling a positive outlook for hard tech in the pharmaceutical sector. Latest data shows that the Huaxia Sci-Tech Biopharma ETF (588130) saw cumulative inflows exceeding RMB 280 million over the past 30 trading days.

In H1 2026, China's innovative drug industry accelerated its global expansion. Out-lic deals surpassed $110 billion, accounting for eight spots among the global top 10 transactions. This marks a shift from 'selling stories' to a new phase of value realization centered on clinical data and commercialization capabilities. Meanwhile, the logic behind medical device exports has strengthened. The FDA's new Remote Regulatory Assessment (RRA) rule, effective August 10, is expected to replace some on-site inspections, significantly compressing certification cycles and costs for high-end Chinese medical devices, directly benefiting the 'front-loading effect' of their overseas revenue.

On the policy front, the state has continued to support 'hard tech' innovative drugs and devices. From elevating biopharma to an 'emerging pillar industry' in the 15th Five-Year Plan, to accelerating review approvals and improving multi-tier payment systems, institutional dividends across the entire chain are being released rapidly, opening long-term growth space for the industry.

Keyuan Securities noted that in 2026, oncology remains the largest area for M&A by multinational pharma companies (MNCs), while autoimmune and neurology sectors are heating up, accelerating industry consolidation and catalyzing a revaluation of R&D value. The Guojin Pharma team is also bullish on the innovative drug and CXO supply chain, believing that as domestic innovative drugs file for US approval en masse and the 2026-2027 turnaround-to-profitability milestone approaches, the industry will enter a 爆发期 (breakout period) of commercial realization.

The Huaxia Sci-Tech Biopharma ETF (588130) offers a low-barrier, one-click tool to access the sector, tracking the SSE Science and Technology Innovation Board Biopharmaceutical Index. The 20% price limit on the Sci-Tech Board provides high elasticity. The index is heavily concentrated in three core tracks: chemical pharmaceuticals, medical devices, and biological products, with a combined weight exceeding 91%, helping ordinary investors capture long-term opportunities in the innovative drug and device sector. (Feeder Fund Class A: 027142; Feeder Fund Class C: 027143).